# New Alzheimer drug trials at Promente

Interview with Robert Kucharski, MD, PhD, about clinical trials of new medicines for Alzheimer disease and participation at Promente.

- Page: https://www.pro-mente.pl/en/blog/new-alzheimers-drug-trials-at-promente/
- Polish version: https://www.pro-mente.pl/badania-nowych-lekow-na-alzheimera-w-promente-wielka-szansa-dla-chorych-i-ich-rodzin/

## A disease-modifying era

Promente is preparing and conducting clinical research into new medicines for Alzheimer disease. These studies may involve people with dementia symptoms, people with mild cognitive impairment and, in selected protocols, people with family risk who may not yet have clinical symptoms.

Robert Kucharski, MD, PhD, explains that neurodegenerative medicine has entered a period of rapid progress. Modern diagnostics can identify disease processes earlier, which creates a chance to use potential disease-modifying treatment before the brain damage becomes advanced.

## What the studies may involve

The center prioritizes phase III studies and mechanisms that have already been partly verified. In this type of research, previous stages have provided information about safety, potential side effects and preliminary efficacy.

Depending on the protocol, studies may include people with visible symptoms, people with mild cognitive impairment and people in whom pathological proteins are already present even before clear memory symptoms appear.

## Diagnosis and monitoring

Pathological protein accumulation can be assessed through cerebrospinal fluid testing or positron emission tomography. Each method has advantages and limitations, and the diagnostic path is chosen with attention to expected benefit, accuracy and burden for the participant.

Neuropsychological testing is also important. It helps determine the participant baseline status and later evaluate whether cognitive functions are stable, improving or worsening during the study.

## Possible duration

Depending on symptom severity and the specific protocol, treatment and observation can last from two to six years. The purpose of this type of research is to determine whether investigational treatment can delay or prevent progression to dementia in selected participants.